Clinicobiological therapeutic stratification leads to excellent prognosis in MYCN-NA disseminated NB patients ≤12 m. Results of SIOPEN LINES trial (was selected for ORAL presentation)

EJC Paediatric Oncology · Published 2026-03-25 · DOI 10.1016/j.ejcped.2025.100425

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcped.2025.100425

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Modern trends in pediatric radiotherapy utilization · EJC Paediatric Oncology · 2026 · Same journal
• Pre-treatment with ferroptosis-inducers enhances NK cell immunotherapy infiltration in high-risk neuroblastoma · EJC Paediatric Oncology · 2026 · Same journal
• Sensitive detection of minimal residual disease and immunotherapy targets by blood and bone marrow multi-modal liquid biopsy analysis in high-risk neuroblastoma · EJC Paediatric Oncology · 2026 · Same journal
• Dosimetric impact of intra- and interfraction motion on organ at risk dose during Volumetric arc therapy Total body irradiation · EJC Paediatric Oncology · 2026 · Same journal
• Paediatric oncology meets palliative care: A road towards a common language · EJC Paediatric Oncology · 2026 · Same journal
• Clinical impact of MFBG vs. MIBG for children with neuroblastoma - a prospective national cohort in Denmark · EJC Paediatric Oncology · 2026 · Same journal
• Intensification of treatment with immunochemotherapy in metastatic high-risk neuroblastoma patients after inadequate induction response (was selected for Fire-session) · EJC Paediatric Oncology · 2026 · Same journal
• Scalp segmentation and permanent alopecia prediction in pediatric craniospinal irradiation: The PAST and HOPE projects · EJC Paediatric Oncology · 2026 · Same journal
• Longitudinal Neuropsychological Outcomes After Pediatric non-CNS Cancer Diagnosis and the Role of Neurological Complications · EJC Paediatric Oncology · 2026 · Same journal
• The gadekill cell product as novel immunotherapeutic tool for neuroblastoma patients · EJC Paediatric Oncology · 2026 · Same journal